Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1375 - Ganoderma Lucidum has immunostimulatory and antinflamatory effect in breast cancer patients (4P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Ramadhan Othman

Citation

Annals of Oncology (2017) 28 (suppl_10): x1-x6. 10.1093/annonc/mdx652

Authors

R. Othman1, H.A. Saeed2, N. Abdulkader3

Author affiliations

  • 1 Medicine, University of Duhok, 1014 am - Duhok/IQ
  • 2 College Of Medcicne, Hawler Medical University, 40/0112 - Hawler/IQ
  • 3 Medicine, Hawler Medical University, 40/0112 - Hawler/IQ
More

Resources

Abstract 1375

Background

Breast cancer (BC) is the most common cancer among women. A key factor in tumour development is evasion of immune detection therefore, the search for alternative medicines with reduced toxicity towards normal tissues as well as ability to improve function of immune system and targets tumours cells has received growing interest. Ganoderma lucidum (GL) have been demonstrated to possess anti-tumour and immunomodulatory activities. Little is known about effects immunomodulatory effect of GL on BC patients when used with chemotherapeutic agents. We aim to investigate the level of immune biomarkers; interferon-γ (IF-γ), tumour necrotic factor-α (TNF-α), inteleukin-8 (IL-8) and adiponectin in these patients.

Methods

Forty female patients with BC were included and divided equally to two groups, group 1 received chemotherapy alone and group 2 received chemotherapy and GL capsules (1000 mg twice daily). Blood samples were obtained from all patients before and after 4 cycles of chemotherapy. These samples were analysed to identify the levels of IF-γ, TNF-α, IL-8 and adiponectin.

Results

After the treatment period, there was significant increase of IF-γ (P = 0.0024) and significant decrease in the mean serum levels of TNF-α (P = 0.0004) and non-significant increase in IL-8 (P = 0.019) in patients treated with concurrent GL and chemotherapy. A non-significant difference was found between pre and post treatment in the mean serum levels of TNF-α, IF-γ, and IL-8 in patients received chemotherapy only. The mean serum levels of adiponectin after receiving chemotherapy only or with GL did not show any significant difference when compared to pre-treatment levels.

Conclusions

Compared to BC patients treated with chemotherapy alone, patients treated with GL and chemotherapy showed significant increase of IF-γ (a marker for immune stimulation effect) and significant decrease in the levels of TNF-α (a marker for anti-inflammation).

Clinical trial identification

Legal entity responsible for the study

Hawler Medical University/College of Pharmacy

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings